<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450190</url>
  </required_header>
  <id_info>
    <org_study_id>26443</org_study_id>
    <nct_id>NCT00450190</nct_id>
  </id_info>
  <brief_title>Saizen® E-Device User Trial</brief_title>
  <official_title>User Trial on the Use in Common Practice of a New Electronic Auto-injector of Saizen®, the E-Device (Electronic Device), in Children Treated by Recombinant Human Growth Hormone Over a Period of 2 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the E-Device performances and handling on the use in
      common practice, by collecting the impressions of patients, nurses and the investigator on
      the graphic interface, the instructions manual, the E-Device training and the material
      itself.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate patients' feedback after 2 weeks of E-Device use with a questionnaire (by phone) on qualitative first global impression of the E-Device and on usefulness and reliability of each E-Device function</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate patients' feedback on the use of E-Device by using a questionnaire: To evaluate the nurse/physician's feedback after the E-Device set up at the inclusion visit and To assess the safety during the treatment and follow-up period of the study</measure>
    <time_frame>Various time points</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Growth Disorders</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electronic device; Electronic Auto-Injector of Saizen®</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients naïve to, or experienced with, Saizen® with growth disorders in registered
             indications (GHD, Turner's Syndrome, Chronic Renal Failure, patient born SGA according
             to the local SmPC)

          2. Written informed consent must be obtained from the parent(s)/legal guardian(s) at the
             beginning of the study. Children able to understand the trial should personally sign
             and date the written informed consent

        Exclusion Criteria:

          1. Known hypersensitivity to somatropin or any of the excipients

          2. Epiphyseal fusion

          3. Active neoplasia (either newly diagnosed or recurrent)

          4. History of intracranial hypertension with papilledema

          5. Diabetes mellitus or history of significant glucose intolerance as defined by a
             fasting blood glucose &gt; 116 mg/dL

          6. Severe congenital malformations

          7. Severe psychomotor retardation

          8. Known hepatic disease as defined by elevated liver enzymes or total bilirubin (x 2 N)

          9. Current congestive heart failure, untreated hypertension, serious chronic oedema of
             any cause

         10. Chronic infectious disease

         11. Previous or ongoing treatment with sex steroid therapy such as estrogens and
             testosterone

         12. Previous or ongoing treatment with any therapy that may directly influence growth,
             including GH, GHRF and long duration corticosteroids therapy

         13. Proliferative or preproliferative diabetic retinopathy

         14. Evidence of any progression or recurrence of an underlying intra-cranial space
             occupying lesion

         15. Precocious puberty

         16. Severe associated pathology affecting growth such as malnutrition, malabsorption or
             bone dysplasia

         17. Concomitant corticoid treatment or levothyroxine treatment other than substitutive
             treatment, topical or inhaled treatment

         18. Participation to any clinical study within the 30 days preceding study entry

         19. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Dominique Roger, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merck Lipha Santé s.a.s., an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <link>
    <url>http://www.saizenus.com</url>
    <description>Full FDA approved prescribing information can be found here</description>
  </link>
  <results_reference>
    <citation>Tauber M, Payen C, Cartault A, Jouret B, Edouard T, Roger D. User trial of Easypod, an electronic autoinjector for growth hormone. Ann Endocrinol (Paris). 2008 Dec;69(6):511-6. doi: 10.1016/j.ando.2008.04.003. Epub 2008 Jun 26.</citation>
    <PMID>18589398</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2007</study_first_submitted>
  <study_first_submitted_qc>March 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <last_update_submitted>February 17, 2014</last_update_submitted>
  <last_update_submitted_qc>February 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Merck Lipha Santé s.a.s., an affiliate of Merck KGaA, Darmstadt, Germany</organization>
  </responsible_party>
  <keyword>Growth disorders/drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Growth Disorders</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 29, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

